Home > Boards > US OTC > Biotechs > NanoLogix, Inc. (NNLX)

Very good update

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Emerald Isle Member Profile
 
Followed By 1
Posts 269
Boards Moderated 0
Alias Born 11/06/13
160x600 placeholder
Emerald Isle   Wednesday, 08/21/19 06:45:07 AM
Re: None
Post # of 10036 
Very good update

NanoLogix Seeks $3 Million For Expansion and Development

Offers Net-Revenue Share of N-Assay Bacteria Diagnostic

NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.

A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.


A direct link to the PowerPoint is here:

http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx


It is also available on our website at: http://nanologix.com/

The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.


Further updates will occur as warranted.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist